company background image
ANAB

AnaptysBioNasdaqGS:ANAB Stock Report

Market Cap

US$750.0m

7D

1.6%

1Y

87.3%

Updated

25 Sep, 2021

Data

Company Financials +
ANAB fundamental analysis
Snowflake Score
Valuation1/6
Future Growth1/6
Past Performance0/6
Financial Health6/6
Dividends0/6

ANAB Overview

AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications.

Price History & Performance

Summary of all time highs, changes and price drops for AnaptysBio
Historical stock prices
Current Share PriceUS$27.34
52 Week HighUS$13.96
52 Week LowUS$35.85
Beta0.066
1 Month Change10.33%
3 Month Change3.40%
1 Year Change87.26%
3 Year Change-72.60%
5 Year Changen/a
Change since IPO60.82%

Recent News & Updates

Shareholder Returns

ANABUS BiotechsUS Market
7D1.6%-2.3%0.1%
1Y87.3%26.1%35.3%

Return vs Industry: ANAB exceeded the US Biotechs industry which returned 26.1% over the past year.

Return vs Market: ANAB exceeded the US Market which returned 35.3% over the past year.

Price Volatility

Is ANAB's price volatile compared to industry and market?
ANAB volatility
ANAB Beta0.066
Industry Beta1.03
Market Beta1

Stable Share Price: ANAB is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: ANAB's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
200594Hamza Suriahttps://www.anaptysbio.com

AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. The company’s products include Imsidolimab, an IL-36R antibody that inhibits the interleukin-36 receptor for the treatment of various dermatological inflammatory diseases; ANB030, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through ANB030 treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. It also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations.

AnaptysBio Fundamentals Summary

How do AnaptysBio's earnings and revenue compare to its market cap?
ANAB fundamental statistics
Market CapUS$750.03m
Earnings (TTM)-US$8.71m
Revenue (TTM)US$101.27m

7.4x

P/S Ratio

-86.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ANAB income statement (TTM)
RevenueUS$101.27m
Cost of RevenueUS$90.61m
Gross ProfitUS$10.67m
ExpensesUS$19.38m
Earnings-US$8.71m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.32
Gross Margin10.53%
Net Profit Margin-8.60%
Debt/Equity Ratio0%

How did ANAB perform over the long term?

See historical performance and comparison

Valuation

Is AnaptysBio undervalued compared to its fair value and its price relative to the market?

1.94x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ANAB's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate ANAB's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: ANAB is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: ANAB is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ANAB's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ANAB is good value based on its PB Ratio (1.9x) compared to the US Biotechs industry average (3.3x).


Future Growth

How is AnaptysBio forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

-8.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ANAB is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ANAB is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ANAB is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ANAB's revenue (12.3% per year) is forecast to grow faster than the US market (9.8% per year).

High Growth Revenue: ANAB's revenue (12.3% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: ANAB is forecast to be unprofitable in 3 years.


Past Performance

How has AnaptysBio performed over the past 5 years?

-23.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ANAB is currently unprofitable.

Growing Profit Margin: ANAB is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ANAB is unprofitable, and losses have increased over the past 5 years at a rate of 23.5% per year.

Accelerating Growth: Unable to compare ANAB's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ANAB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).


Return on Equity

High ROE: ANAB has a negative Return on Equity (-2.26%), as it is currently unprofitable.


Financial Health

How is AnaptysBio's financial position?


Financial Position Analysis

Short Term Liabilities: ANAB's short term assets ($398.1M) exceed its short term liabilities ($20.6M).

Long Term Liabilities: ANAB's short term assets ($398.1M) exceed its long term liabilities ($20.2M).


Debt to Equity History and Analysis

Debt Level: ANAB is debt free.

Reducing Debt: ANAB has no debt compared to 5 years ago when its debt to equity ratio was 10.9%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable ANAB has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: ANAB is unprofitable but has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by 25.8% per year.


Dividend

What is AnaptysBio current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ANAB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ANAB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ANAB's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ANAB's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ANAB's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.4yrs

Average management tenure


CEO

Hamza Suria (45 yo)

10.17yrs

Tenure

US$885,390

Compensation

Mr. Hamza Suria, M.Sc., M.B.A. has been the Chief Executive Officer and President of AnaptysBio, Inc., since July 2011. Mr. Suria served as an Acting Chief Executive Officer and Chief Business Officer of A...


CEO Compensation Analysis

Compensation vs Market: Hamza's total compensation ($USD885.39K) is below average for companies of similar size in the US market ($USD2.30M).

Compensation vs Earnings: Hamza's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: ANAB's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.


Board Members

Experienced Board: ANAB's board of directors are considered experienced (3.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

AnaptysBio, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: AnaptysBio, Inc.
  • Ticker: ANAB
  • Exchange: NasdaqGS
  • Founded: 2005
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$750.028m
  • Shares outstanding: 27.43m
  • Website: https://www.anaptysbio.com

Number of Employees


Location

  • AnaptysBio, Inc.
  • 10421 Pacific Center Court
  • Suite 200
  • San Diego
  • California
  • 92121
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/09/25 22:02
End of Day Share Price2021/09/24 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.